Abstract
The melanocortin-3 receptor (MC3R) is a G protein-coupled receptor involved in regulating energy metabolism, cardiovascular function, and inflammation. To gain a better understanding of the structure-function relationship of the MC3R, we used alaninescanning mutagenesis to investigate the functions of residues 247–273 in the third intracellular loop (ICL3) of the human MC3R (hMC3R). Ligand binding and signaling parameters of the mutants were measured. The results showed that six mutants at the N terminus of ICL3 had decreased receptor occupancy (an estimate of relative binding capacity) whereas six mutants at the C terminus of ICL3 had increased receptor occupancy. M247A, R252A, H254A, and K256A had decreased maximal responses (M247A also had increased EC50) whereas F250A, P262A, and H272A had increased maximal responses. None of the mutants was constitutively active. The binding and signaling properties of the other mutants were not significantly different from that of the wild type hMC3R. In summary, we presented detailed functional data on the functions of the residues in ICL3 of hMC3R, providing important constraints for modeling ligand binding and G protein coupling/activation in the hMC3R.
Keywords: Melanocortin-3 receptor, alanine scanning mutagenesis, binding, signaling.
Current Pharmaceutical Design
Title:Functions of the Third Intracellular Loop of the Human Melanocortin-3 Receptor
Volume: 19 Issue: 27
Author(s): Zhi-Qiang Wang and Ya-Xiong Tao
Affiliation:
Keywords: Melanocortin-3 receptor, alanine scanning mutagenesis, binding, signaling.
Abstract: The melanocortin-3 receptor (MC3R) is a G protein-coupled receptor involved in regulating energy metabolism, cardiovascular function, and inflammation. To gain a better understanding of the structure-function relationship of the MC3R, we used alaninescanning mutagenesis to investigate the functions of residues 247–273 in the third intracellular loop (ICL3) of the human MC3R (hMC3R). Ligand binding and signaling parameters of the mutants were measured. The results showed that six mutants at the N terminus of ICL3 had decreased receptor occupancy (an estimate of relative binding capacity) whereas six mutants at the C terminus of ICL3 had increased receptor occupancy. M247A, R252A, H254A, and K256A had decreased maximal responses (M247A also had increased EC50) whereas F250A, P262A, and H272A had increased maximal responses. None of the mutants was constitutively active. The binding and signaling properties of the other mutants were not significantly different from that of the wild type hMC3R. In summary, we presented detailed functional data on the functions of the residues in ICL3 of hMC3R, providing important constraints for modeling ligand binding and G protein coupling/activation in the hMC3R.
Export Options
About this article
Cite this article as:
Wang Zhi-Qiang and Tao Ya-Xiong, Functions of the Third Intracellular Loop of the Human Melanocortin-3 Receptor, Current Pharmaceutical Design 2013; 19 (27) . https://dx.doi.org/10.2174/1381612811319270005
DOI https://dx.doi.org/10.2174/1381612811319270005 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Attenuation of Microvascular Injury in Preconditioned Ischemic Myocardium: Imaging with Tc-99m Glucaric Acid and In-111 Human Fibrinogen
Current Molecular Imaging (Discontinued) Recent Development of Hydrogen Sulfide Therapeutics in the Treatment of Cardiovascular Diseases
Current Topics in Medicinal Chemistry Use of Recombinant Factor VII in Cardiac Surgery
Recent Patents on Cardiovascular Drug Discovery Life and Death of Nerve Cells: Therapeutic Cytokine Signaling Pathways
Current Signal Transduction Therapy Novel Treatments in Diabetic Nephropathy
Current Hypertension Reviews Epigenetic Mechanisms and Kidney Diseases
Current Medicinal Chemistry Neuroprotective Effects of <i>Nardostachys jatamansi</i> Against BSO Induced Anxiety via its Antioxidant Machinery and by Elevating Catecholamines and GABA levels in Mice
Current Traditional Medicine Embolic Protection Devices in Saphenous Vein Graft and Native Vessel Percutaneous Intervention: A Review
Current Cardiology Reviews The Therapeutic Role of Taurine in Ischaemia-Reperfusion Injury
Current Pharmaceutical Design The Role of Anticoagulation in IPF
Current Respiratory Medicine Reviews Alogliptin; A Review of a New Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Cardiovascular & Hematological Disorders-Drug Targets Strategies for Leukotriene Modulation in Dermatology: Even More Visionary Perspectives? An Update
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Pleiotropic Effects of Simvastatin on Some Calcium Regulatory and Myofibrillar Proteins in Ischemic/Reperfused Heart: Causality of Statins Cardioprotection?
Current Pharmaceutical Design The HVJ-Envelope as an Innovative Vector System for Cardiovascular Disease
Current Gene Therapy Editorial (Thematic Issue: Calcium in Heart Disease: The Ubiquitous Ion)
Medicinal Chemistry Targeting Vascular Redox Biology Through Antioxidant Gene Delivery: A Historical View and Current Perspectives
Recent Patents on Cardiovascular Drug Discovery Blood Biomarkers in Cardioembolic Stroke
Current Cardiology Reviews The Glutathione System and its Regulation by Neurohormone Melatonin in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions
Current Signal Transduction Therapy Essentials of Daflon 500 mg: From Early Valve Protection to Long-Term Benefits in the Management of Chronic Venous Disease
Current Pharmaceutical Design